Semaglutide 14 mg (Rybelsus) is the maximum oral maintenance dose used with diet and exercise to improve blood sugar control in adults with type 2 diabetes after at least 30 days on 7 mg when additional A1C lowering is needed. Its typical benefits include further A1C reduction and possible weight loss, though it is not approved as a weight‑loss drug. Common side effects are nausea, diarrhea, abdominal pain, decreased appetite, vomiting, and hypoglycemia when combined with insulin or sulfonylureas.